Navigation Links
BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer

- Strategic Collaboration with the Gynecologic Oncology Group -

BRISBANE, Calif., May 28 /PRNewswire/ -- BiPar Sciences, Inc. today announced it has expanded its clinical trials program through the initiation of an additional Phase 2 study of its lead product candidate BSI-201. The trial will assess BSI-201, the first ADP-ribose polymerase (PARP) inhibitor in the company's DNA repair portfolio, for the treatment of uterine carcinosarcoma or malignant mixed mullerian tumors.

This multi-center, open-label, single-arm study in patients with recurrent or advanced uterine carcinosarcomas will evaluate BSI-201 in combination with standard treatment and is being conducted by the Gynecologic Oncology Group, a National Cancer Institute-funded research organization which focuses on gynecologic malignancies. The primary objective of this trial is to determine the antitumor activity of BSI-201 plus carboplatin/paclitaxel in patients with recurrent or advanced uterine carcinosarcomas.

The identification of mixed mullerian tumors of the uterus as a target for its PARP inhibitor was the result of BiPar's ground-breaking work that assessed PARP1 gene expression across all types of human cancers. Striking up- regulation of the PARP gene was a characteristic of cancer of female reproductive organs -- breast, ovary and uterus. PARP over-expression was particularly intense in uterine mixed mullerian tumors, a cancer for which there is no well established standard, effective treatment. BSI-201 blocks a pathway by which tumor cells resist the effects of DNA damaging chemotherapy. Therefore BSI-201 may work to potentiate the effects of current therapies for uterine cancer.

"Current treatments for uterine carcinosarcoma remain limited and are often poorly tolerated," said Carol Aghajanian, M.D., chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center and the Study Chair for this Gynecologic Oncology Group investigation. "The combination of a PARP inhibitor such as BSI-201 which specifically targets uterine tumors in a unique way may boost the effects of common chemotherapy regimen. We hope this drug will play a transformative role in the way we approach treatment."

Uterine cancer is the most common gynecological tumor, and the fourth most-common type of tumor in women. Forty thousand new diagnoses are made each year in the United States.

"Because PARP is expressed at high levels in uterine cancer and particularly MMT, we believe that BSI-201 has the potential to selectively target these highly aggressive and poorly treated tumors," said BiPar Executive Vice President Barry Sherman, M.D. "This will be our third study designed around our gene expression data, which has been invaluable in selecting types of cancer that will most likely respond to PARP inhibition."

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain, uterine and ovarian cancer.

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
2. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
3. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
6. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: AGN ... the New York State Attorney General,s ... Sherman Act, and other statutes with the Attorney General over ... to cease marketing and selling the now generic version of ... admits no liability, has released its counterclaims against ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of ... server to improve system efficiency and reliability. , The new Q-Suite 6 platform is ... the system avoids locking itself into a specific piece of software for many key ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
(Date:11/25/2015)... ... ... On November 10, 2015, Bohrer Brady, LLC filed a class and collective ... home health care worker who provided companionship services for the elderly, ill or disabled ... Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since January ...
Breaking Medicine News(10 mins):